NASDAQ: AKYAAkoya Biosciences Inc Stock
$3.00+0.11 (+3.81%)
Updated Oct 11, 2024
AKYA Price
$3.00
Fair Value Price
N/A
Market Cap
$148.50M
52 Week Low
$1.88
52 Week High
$6.31
P/E
-2.48x
P/B
6.67x
P/S
1.24x
PEG
N/A
Dividend Yield
N/A
Revenue
$93.22M
Earnings
-$60.35M
Gross Margin
57.6%
Operating Margin
-54.17%
Profit Margin
-64.7%
Debt to Equity
5.46
Operating Cash Flow
-$51M
Beta
1.47
Next Earnings
Nov 6, 2024
Ex-Dividend
N/A
Next Dividend
N/A
AKYA Overview
Akoya Biosciences, Inc. provides spatial biology solutions focused on transforming discovery and clinical research. Spatial biology technology enables academic and biopharma scientists to detect and map the distribution of cell types and biomarkers across whole tissue samples at single-cell resolution, which helps to understand disease progression and patient responses to therapy. Its flagship products include PhenoCycler, PhenoImager, and PhenoImager HT. The company was incorporated in 2015 and is headquartered in Marlborough, MA.
Zen Score
–
Industry Average (29)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how AKYA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AKYA is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
AKYA is poor value based on its book value relative to its share price (6.67x), compared to the US Medical Instruments & Supplies industry average (3.97x)
P/B vs Industry Valuation
AKYA is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more AKYA due diligence checks available for Premium users.
Be the first to know about important AKYA news, forecast changes, insider trades & much more!
AKYA News
Valuation
AKYA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.48x
Industry
-60.76x
Market
27.31x
AKYA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
6.67x
Industry
3.97x
AKYA is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
AKYA's financial health
Profit margin
Revenue
$23.2M
Net Income
-$13.1M
Profit Margin
-56.8%
AKYA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
AKYA's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$143.7M
Liabilities
$121.5M
Debt to equity
5.46
AKYA's short-term assets ($89.51M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AKYA's short-term assets ($89.51M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AKYA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$11.0M
Investing
$9.1M
Financing
-$2.1M
AKYA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
AKYA vs Medical Stocks
Akoya Biosciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.